

## KaloBios Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 20-Jun-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 12

    Phase 2 Clinical..... 13

    Phase 1 Clinical..... 25

[Return to Table of Contents](#)

# KaloBios Pharmaceuticals Inc

## COMPANY OVERVIEW

<b>Company Name</b>	KaloBios Pharmaceuticals Inc
<b>Parent Company Name</b>	KaloBios Pharmaceuticals Inc
<b>Website</b>	http://kalobios.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	3
<b>Number of Inactive Drugs</b>	1
<b>Number of Patents as Owner</b>	17
<b>Number of Patents as Third Party</b>	2
<b>Number of Deals</b>	14
<b>Key Indications</b>	Asthma,Cancer,Chronic myelocytic leukemia,Cystic fibrosis,Rheumatoid arthritis,Hematological neoplasm,Inflammatory disease,Pseudomonas infection,Unidentified indication,Acute myelogenous leukemia,Cardiac failure,Chronic obstructive pulmonary disease,Pseudomonas aeruginosa
<b>Key Target-based Actions</b>	Epha3 tyrosine kinase receptor inhibitor,Immunoglobulin G1 modulator,Immunoglobulin kappa modulator,GM-CSF receptor antagonist,GM-CSF ligand inhibitor,ACE inhibitor,VEGF receptor antagonist,Acetylcholinesterase inhibitor,Beta amyloid antagonist,Complement C3 inhibitor,Complement Factor B inhibitor,EGF like module receptor antagonist,EPHA3 gene inhibitor,EPHA3 gene modulator,Epha3 tyrosine kinase receptor modulator,Epha3 tyrosine kinase receptor stimulator,GCSF receptor antagonist,Immunoglobulin G agonist,NMDA receptor antagonist,PcrV protein type III inhibitor,Prokineticin receptor-2 antagonist
<b>Key Technologies</b>	Monoclonal antibody humanized,Biological therapeutic,Infusion,Intravenous formulation,Antibody,Monoclonal antibody,Drug combination,Antibody fragment,Chimeric antibody,Antibody polyclonal

## COMPANY PROFILE

### SUMMARY

KaloBios Pharmaceuticals is engaged in the development of patient-targeted, first-in-class monoclonal antibodies designed to significantly improve the lives of seriously ill patients with difficult-to-treat diseases. Such uses include de novo discovery of high-affinity human antibodies, as well as optimization of antibodies and other therapeutic proteins. KaloBios has the capability to discover, engineer and develop clinically relevant antibodies, protein therapeutics, and small molecules, but is also actively seeking genomics, biotechnology and pharmaceutical collaborators to use its technologies, and to partner and co-develop its drugs.

### ACQUISITIONS AND SPIN-OFFS

In January 2004, KaloBios merged with Celscia Therapeutics. The resulting company was named KaloBios.

### LICENSING AGREEMENTS

In October 2008, BioWa licensed non-exclusive rights to its POLLITIGENT platform to KaloBios Pharmaceuticals for enhancing the antibody-dependent cellular cytotoxicity of select KaloBios therapeutic antibodies.

In April 2007, Novartis non-exclusively licensed KaloBios' Humaneering technology for the development of human antibodies. KaloBios had previously humanized three antibodies for Novartis, and would generate three more. In May 2006, KaloBios humanized an antibody against an undisclosed target for Novartis. The companies also extended their agreement. KaloBios received research and success fees and would receive milestones and royalties.

In June 2004, KaloBios licensed a murine monoclonal antibody for the potential treatment of Pseudomonas aeruginosa infection from the Medical College of Wisconsin and the University of California San Francisco.

[Return to Table of Contents](#)



## FINANCIAL

In January 2013, the company priced the initial public offering of 8,750,000 shares of common stock at a price of \$8 each to the public. The underwriters were granted a 30-day option to purchase up to 1,312,500 additional shares at the same price to cover over-allotments, if any. In February 2013, KaloBios completed the initial public offering, raising gross proceeds of \$70 million, and net proceeds of approximately \$62 million.

In October 2012, the company was planning an IPO of its stock.

In September 2012, the company had completed a \$10 million long-term debt financing with MidCap Financial SBIC and also the company have the option to borrow an additional \$5 million by the end of the second quarter of 2013.

By September 2012, the company had raised gross proceeds of \$20.25 million from the closing of series E financing round.

In September 2008, KaloBios raised \$20 million from a series D financing round. In December 2008, the company raised a further \$12 million from the financing.

In July 2007, KaloBios completed a \$20 million series C financing round.

In March 2005, KaloBios completed a \$20 million series B financing. Proceeds from the financing would be used to build a clinical development team and to progress two lead antibodies into clinical evaluation.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

Indication	Active	Inactive	Total
Musculoskeletal disease	1	1	2
Respiratory disease	2	0	2
Neoplasm	2	0	2
Inflammatory disease	1	1	2
Immune disorder	1	1	2
Hematological disease	2	0	2
Degeneration	0	1	1
Infectious disease	1	0	1
Neurological disease	0	1	1
Dermatological disease	0	1	1
Gastrointestinal disease	1	0	1
Unidentified indication	1	0	1

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



[Return to Table of Contents](#)



## Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
Phase 1 Clinical	1
No Development Reported	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	2	0	1	0	3
Drug - Funding	4	0	0	0	4
Drug - Early Research/Development	0	0	3	0	3
Drug - Development/Commercialization License	1	0	3	0	4

## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Immune disorder	2	7
Inflammatory disease	1	6
Respiratory disease	2	5
Musculoskeletal disease	0	4
Hematological disease	1	2
Gastrointestinal disease	1	2
Dermatological disease	0	1
Neoplasm	1	1
Infectious disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	2	4
Phase 1	1	7
Phase not specified	0	1

[Return to Table of Contents](#)



## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	5	1	6
Endocrine disease	2	0	2
Gastrointestinal disease	4	0	4
Genitourinary disease	1	0	1
Growth disorder	1	0	1
Hematological disease	5	0	5
Degeneration	2	0	2
Andrology	1	0	1
Immune disorder	6	1	7
Musculoskeletal disease	3	0	3
Neoplasm	8	0	8
Genetic disorder	1	0	1
Metabolic disorder	2	0	2
Neurological disease	4	0	4
Prophylaxis	1	0	1
Respiratory disease	4	1	5
Infectious disease	5	0	5
Injury	1	0	1
Unidentified indication	1	0	1
Inflammatory disease	4	1	5
Gynecology and obstetrics	1	0	1

[Return to Table of Contents](#)



Dermatological disease	3	0	3
------------------------	---	---	---

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### KB-003

#### KB-003 SNAPSHOT

<b>Drug Name</b>	KB-003
<b>Key Synonyms</b>	
<b>Originator Company</b>	Ludwig Institute for Cancer Research
<b>Active Companies</b>	KaloBios Pharmaceuticals Inc
<b>Inactive Companies</b>	Ludwig Institute for Cancer Research
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Chronic myelocytic leukemia;Rheumatoid arthritis;Asthma;Inflammatory disease;Unidentified indication
<b>Target-based Actions</b>	Immunoglobulin G1 modulator;GM-CSF ligand inhibitor;Immunoglobulin kappa modulator
<b>Other Actions</b>	Anticancer monoclonal antibody;Anti-inflammatory
<b>Technologies</b>	Monoclonal antibody human;Intravenous formulation;Infusion;Biological therapeutic;Parenteral formulation unspecified
<b>Last Change Date</b>	19-Jun-2013

#### KB-003 DEVELOPMENT PROFILE

##### SUMMARY

KaloBios, under license from the Ludwig Institute for Cancer Research, is developing the anti-GM-CSF human IgG1 kappa monoclonal antibody KB-003, a Humaneered (engineered human antibody) version of the prototype antibody KB-002, for the potential treatment of inflammatory diseases such as rheumatoid arthritis (RA) and asthma, and also for an undisclosed indication,. The company is also investigating the mAb for the potential treatment of chronic myelomonocytic leukemia. In December 2009, a phase II trial began in patients with RA. By May 2011, a phase IIb trial for KB-003 had been initiated for an undisclosed indication. In September 2012, a phase II trial for asthma was initiated ; in May 2013, topline results were expected in the first quarter of 2014.. In July 2011, the company was seeking to outlicense KB-003.

In November 2006, a phase I RA trial of KB-002 began ; in May 2008, the drug was listed as in phase I/II for this indication of the company's pipeline ; by May 2011, the trial had been completed. In March 2008, a phase I/II trial of KB-002 for persistent asthma began ; by May 2011, the trial had been completed. In February 2013, data were presented . In May 2008, the company planned to cease development of KB-002 in 2008 ; by July 2011, development of KB-002 was presumed to be ceased as the company planned to concentrate on KB-003 for all the future developments.

The company was previously investigating anti-GM-CSF antibodies for the potential treatment of multiple sclerosis, chronic obstructive pulmonary disease, psoriasis and Alzheimers disease; however, no further development was reported for these indications since 2009.

[Return to Table of Contents](#)



## KB-003 DEVELOPMENT STATUS

### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
KaloBios Pharmaceuticals Inc	Asthma	Australia	Phase 2 Clinical	10-Mar-2008
KaloBios Pharmaceuticals Inc	Asthma	Europe	Phase 2 Clinical	10-Jan-2013
KaloBios Pharmaceuticals Inc	Asthma	US	Phase 2 Clinical	14-Aug-2012
KaloBios Pharmaceuticals Inc	Rheumatoid arthritis	Australia	Phase 2 Clinical	20-May-2008
KaloBios Pharmaceuticals Inc	Rheumatoid arthritis	US	Phase 2 Clinical	04-Dec-2009
KaloBios Pharmaceuticals Inc	Unidentified indication	US	Phase 2 Clinical	10-May-2011
KaloBios Pharmaceuticals Inc	Inflammatory disease	US	Phase 1 Clinical	11-Nov-2006
KaloBios Pharmaceuticals Inc	Chronic myelocytic leukemia	US	Discovery	10-Dec-2012
KaloBios Pharmaceuticals Inc	Thrombocytopenic purpura	Australia	Discontinued	23-Nov-2010
Ludwig Institute for Cancer Research	Autoimmune disease	Australia	Discontinued	04-May-2004
KaloBios Pharmaceuticals Inc	Alzheimers disease	US	No Development Reported	21-Apr-2011

### KB-003 DRUG NAMES

Names	Type
KB-003	Research Code
anti-GM-CSF mAb (inflammatory disease/rheumatoid arthritis/asthma), KaloBios	
KB-002	Research Code
anti-GM-CSF mAb (autoimmune disease), Ludwig/KaloBios	

### KB-003 CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Rheumatoid arthritis											
0	0	0	0	0	1	0	3	0	0	0	4

[Return to Table of Contents](#)

Asthma											
0	0	0	0	1	1	0	1	0	1	1	3
Thrombocytopenic purpura											
0	0	0	0	0	0	0	1	0	0	0	1
Inflammatory disease											
0	0	0	0	0	0	0	1	0	0	0	1
Autoimmune disease											
0	0	0	0	0	0	0	1	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	5	0	1	1	8

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

KB-003 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
KaloBios Pharmaceuticals Inc	1	0	1	0	2
Ludwig Institute for Cancer Research	1	0	0	0	1
US Government	0	0	1	0	1

Deals by Type Chart



Deals by Type Table


Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1

[Return to Table of Contents](#)



PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
KaloBios Pharmaceuticals Inc	5	0	5
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	2
Product	1
Tentative	1
Component of Combination	1

## KB-001

### KB-001 SNAPSHOT

Drug Name	KB-001
Key Synonyms	
Originator Company	University of California San Francisco
Active Companies	KaloBios Pharmaceuticals Inc;Sanofi Pasteur
Inactive Companies	University of California San Francisco
Highest Status	Phase 2 Clinical
Active Indications	Cystic fibrosis;Pseudomonas infection
Target-based Actions	PcrV protein type III inhibitor
Other Actions	Antibacterial
Technologies	Monoclonal antibody humanized;PEGylated formulation;Intravenous formulation;Biological therapeutic
Last Change Date	24-Apr-2013

### KB-001 DEVELOPMENT PROFILE

#### SUMMARY

Sanofi Pasteur (a division of Sanofi) and KaloBios, under license from the University of California San Francisco, are developing the iv PcrV-neutralizing KB-001 (KB-001A), the lead in a series of Humanized PEGylated monoclonal antibody fragments that includes 1A8, for the potential treatment of life-threatening Pseudomonas infection . KaloBios is also developing the drug for the potential treatment of cystic fibrosis (CF). As of January 2010, Sanofi Pasteur would focus on hospital-acquired infections, including prevention in mechanically-ventilated patients, while KaloBios would remain focused on treating infections in patients with cystic fibrosis and bronchiectasis. In January 2013, a phase II trial was initiated with cystic fibrosis patients with Pseudomonas auregenosa infections and at that time, results were expected in mid-2014 . In March 2008, a phase I/II trial in cystic fibrosis patients with Pseudomonas infections was initiated ; by June 2011, the drug had completed phase I/II for cystic fibrosis. A second phase I/II trial began in May 2008 ; in June 2012, results from the phase IIa trial were reported. In June 2012, Sanofi was planning for larger clinical trials for Pseudomonas aeruginosa infection in mechanically-ventilated patients. In January 2013, KaloBios was planning to develop a sc formulation of KB-001.

### KB-001 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
KaloBios Pharmaceuticals Inc	Cystic fibrosis	US	Phase 2 Clinical	30-Jun-2011
KaloBios Pharmaceuticals Inc	Pseudomonas infection	France	Phase 2 Clinical	19-May-2008
KaloBios Pharmaceuticals Inc	Pseudomonas infection	US	Phase 2 Clinical	31-Mar-2008

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Sanofi Pasteur	Pseudomonas infection	France	Phase 2 Clinical	11-Jan-2010
University of California San Francisco	Pseudomonas infection	US	Discontinued	02-Jun-2004

## KB-001 DRUG NAMES

Names	Type
monoclonal antibodies (iv, Pseudomonas aeruginosa), KaloBios/Sanofi Pasteur	
1A8	Research Code
KB-001a	Research Code
KB-001	Research Code

## KB-001 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Cystic fibrosis											
0	0	0	0	1	1	0	1	0	0	1	2
Pseudomonas aeruginosa infection											
0	0	0	0	0	1	0	0	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	2	0	1	0	0	1	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


[Return to Table of Contents](#)



## KB-001 DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart




#### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
KaloBios Pharmaceuticals Inc	2	0	1	0	3
US Government	0	0	1	0	1
Sanofi	0	0	1	0	1
University of California	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2
Drug - Funding	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
KaloBios Pharmaceuticals Inc	4	0	4
University of California	2	0	2
Medical College of Wisconsin	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Component of Combination	1
New use	1



## KB-004

### KB-004 SNAPSHOT

Drug Name	KB-004
Key Synonyms	
Originator Company	KaloBios Pharmaceuticals Inc
Active Companies	KaloBios Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Cancer;Hematological neoplasm
Target-based Actions	Immunoglobulin G1 modulator;Epha3 tyrosine kinase receptor inhibitor;Immunoglobulin kappa modulator
Other Actions	Anticancer monoclonal antibody;Anticancer protein kinase inhibitor
Technologies	Monoclonal antibody humanized;Intravenous formulation;Infusion;Biological therapeutic
Last Change Date	28-Mar-2013

### KB-004 DEVELOPMENT PROFILE

#### SUMMARY

KaloBios is developing KB-004, an IgG1 kappa monoclonal antibody that binds to the EphA3 tyrosine kinase receptor expressed on the surface of tumor cells, engineered using the company's Humaneering technology, for the potential iv infusion treatment of cancer, including hematological malignancies,. By January 2011, a phase I trial in patients with hematological malignancies had been initiated ; in January 2013, the drug was listed as being in phase I development. In March 2013, the company was planning to complete the enrollment and at that time, the company was planning to initiate a phase II study for at least one new indication in the first quarter of 2014. In July 2011, the company was planning on seeking to outlicense its programs while retaining rights to patient-targeted orphan indications in the US.

### KB-004 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
KaloBios Pharmaceuticals Inc	Hematological neoplasm	US	Phase 1 Clinical	11-Jan-2011
KaloBios Pharmaceuticals Inc	Cancer	US	Discovery	20-May-2008

[Return to Table of Contents](#)



## KB-004 DRUG NAMES

Names	Type
KB-004	Research Code
anti-EphA3 tyrosine kinase receptor monoclonal antibody (Humaneered, iv, cancer), KaloBios	

## KB-004 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Chronic lymphocytic leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Myelodysplastic syndrome											
0	0	0	0	0	0	1	1	0	0	1	1
Multiple myeloma											
0	0	0	0	0	0	1	1	0	0	1	1
Acute myelogenous leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Chronic myelocytic leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Acute lymphoblastic leukemia											
0	0	0	0	0	0	1	1	0	0	1	1
Neoplasm											
0	0	0	0	0	0	1	1	0	0	1	1

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	1	0	0	1	1

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## KB-004 DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart



Active Deals  
Total: 7




[Return to Table of Contents](#)

### Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
KaloBios Pharmaceuticals Inc	4	0	3	0	7
University of Turin	1	0	0	0	1
US Government	0	0	1	0	1
Queensland Institute of Medical Research	1	0	0	0	1
Cancer Australia	0	0	1	0	1
Prostate Cancer Foundation of Australia	0	0	1	0	1
Ludwig Institute for Cancer Research	1	0	0	0	1
Australian Government	0	0	1	0	1

### Deals by Type Chart




### Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	4	0	4
Drug - Early Research/Development	3	0	3

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
KaloBios Pharmaceuticals Inc	6	0	6
Monash University	2	0	2
Ludwig Institute for Cancer Research	2	0	2
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
New use	2
Formulation	1
General interest	1
Product	1
Process	1

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

